New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2013
08:03 EDTTKPYY, AFFYAnemia drug had side effects soon after it went on the market, WSJ reports
As the FDA evaluates the anemia drug Omontys, used in kidney dialysis patients, life-threatening reactions to it began appearing within months of when the treatment went on the market, according to a review of regulatory records, reports the Wall Street Journal. The drug, from Affymax Inc. (AFFY) and Takeda Pharmaceutical Co. (TKPYY), was linked to allergic reactions and respiratory distress beginning in August 2012, soon after it went on the U.S. market in late April. Reference Link
News For AFFY;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
05:16 EDTTKPYYTeva enters partnership with Takeda Pharmaceutical
Subscribe for More Information
November 20, 2015
16:55 EDTTKPYYTakeda confirms FDA approval of Ninlaro
Takeda Pharmaceutical Company Limited announced that the FDA has approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
10:52 EDTTKPYYFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use